

TITLE: Regulatory Compliance Impact Assessment - Template $\mbox{\bf REV.:}\;\;\mbox{\bf C}$

REGULATOR	RY COMPLIAN	NCE IMP	ACT ASSESS	MENT		
⊠ EPD □ EC	R □ GEPC	Nu	mber: EPD-00	4881	CAPA Ass	ociated: No
☐ <insert other=""></insert>			Level: L2L		CAPA ID:	N/A
Problem Statem	ent / Change Sco	ре				
	nt part, Hubbel GF					
Requested Action	on: Replace part w	ith the Hubl	oel GRF15W. Ne	ed to qualify new pa	art for LRF.	
Description of th	ne Product					
GFCI is used in chr	omatography assem	bly placed ins	ide TSX & TSG un	its		
Affected Produc	t Family / Model(s) and Acce	ssories (Do not	embed documents f	for PDF visibility)	
Models: -						
	romatography) A-vo					
TSX2305CA	TSX3005CA	TSX4505CA	TSX5005C	A		
TSX2305CD	TSX3005CD	TSX4505CD	TSX5005C	D		
TSX2305CY	TSX3005CV	TSX4505CY	TSX5005C	Y		
TSX2305CZ	TSX3005CY	TSX4505CZ	TSX5005C	Z		
CH2305CA	CH3005CA	CH4505CA	CH5005CA	`		
TSG2305CA	TSG3005CA	TSG4505CA	TSG5005C	A		
Accessories: N/A Refer attached wh	Accessories: N/A Refer attached where used.					
				GENERAL		
Impact to Manu						
Design Owner:	ASH	•	applicable): NA		Name of OEM (if applica	able): N/A
Manufacturing Sit	e: ⋈ AVL ⊔ MAR L Other (if applica		A □ SNG □ Othe	r □ OEM □ CM (Exteri Name of OEM (if app	•	
	CM (External – if			Name of Ocivi (if app	iicabiej.	
Design is Copy Exa		. аррисавіс).				
	to be created in sco	pe of this pro	oject:			
N/A						
Device Type (ha	sed on Intended U	Ise) and Kno	own Markets			
				se for the product (refe	rence the products User Man	ual). If the product family
				pes must be selected.	·	
	Devic	е Туре	N. America	EMEA	LATAM	APAC
	General Purpos	se (GP)	\boxtimes			
	Medica	al (MD)		\boxtimes		
In Vitro Diagnostics (IVD)						
	In Vitro Diagnostic	cs (IVD)			_	
Gen Purpose + Ce	In Vitro Diagnostic Il Gene Therapy (GP					
Gen Purpose + Ce		+ CGT)				
	ll Gene Therapy (GP	+ CGT) Scope + CGT)				



TITLE: Regulatory Compliance Impact Assessment **REV.:** C

	RISK MANAGEMENT FILE IMPACT (All products)
	The change does not impact the Risk Management File
Just	ification: This is a drop-in replacement for GFCI, The RMF for TSX series 329376I01-03 is not impacted with the said change.
	Mark where applicable
	☐ The product family does not have a Risk Management File or does not have a Risk Management File aligned to the latest revisions in the QMS.
	The change introduces new usage conditions, or risk of harm as defined in the Risk Management Procedure (<i>Patient, Samples, Operators, Environment,</i>
	etc.).
	☐ The change <u>affects the current risk probability or severity</u> associated with existing hazards ☐ The change will mean that the device will have different end users or be used in a different manner
Scope Assessment	☐ The performance evaluation data for the original device is not sufficient to confirm conformity of the changed device with the required characteristics
	and performance
	☐ The change involves the manufacturing process (i.e., technologies, product lines)
ASS	☐ The change impacts End of Line (EOL) testing procedures (e.g., TP902 – Test procedure for all Hi Pot and Hypatia Equipment Test Machines)
e/	☐ The change requires a process validation
8	☐ The change affects agreements and/or arrangements (e.g., verification, validation, organizational structure, production site, outsourcing, subcontracting)
Š	for ensuring continued compliance with the requirements
	☐ The change results from actions taken related to concerns arising from post-market surveillance including incidents/recalls/complaints (CAPA associated)
	☐ The change impacts Quality Control procedures, incoming acceptance criteria, or involves a change in supplier
	☐ (Medical) The change results from characteristics not previously considered in the clinical evaluation
	☐ (Medical) The change is driven by the development of the state of the art (e.g., latest technology)
	☐ Other: < If "Other" is selected, provide more information here>
ons	Next Steps: <choose action="" assessment.="" based="" be="" completed="" item="" need="" on="" project="" scope="" that="" the="" to="" would=""></choose>
ţ	GEPC# (if applicable):
ţ	Other (if applicable): f "Other" is selected, provide more information here Notifications to:
Project Actions	□ CAPA owner notified
<u> </u>	
	PRODUCT SPECIFIC COMPLIANCE ASSESSMENT (All products)
\boxtimes	The change does not impact the performance compliance of the product.
Just	ification: This change does not affect product specific compliance since the project scope drop-in replacement for GFCI part.
	Mark where applicable
	*Clean Room Impact Determination:
	☐ Changes affect degradable, moving or friction generating components (air filters, fans, hinges, etc.) ☐ Changes affect the airflow into, throughout, and out of the unit (airflow vent, rearranging components, deck size, etc.)
	☐ Product currently has outdated testing or missing testing to the latest requirements. Requested to add in scope of the current project.
	*Energy Star Impact Determination (Refrigerators/Freezers/ULT only):
	☐ Changes affect critical components in compliance files (Electrical, refrigeration, labels)
	☐ Changes affect the product performance, peak variation, temperature stability, door open recovery times
Assessment	☐ Changes will be made to the product power specifications, refrigeration system, or electrical systems
Sm	☐ Changes to the internal cabinet size, construction, or configuration (inner doors, shelving, port holes)
ses	☐ Change to defrosts, setpoint ranges, or code versions
	☐ Changes to the software affecting behavior or timing of behaviors
Scope	☐ Product currently has outdated testing or missing testing to the latest requirements. Requested to add in scope of the current project.
SC	ErP Impact Determination (Chillers: Low Temperature / Medium Temperature / Height Temperature)
	☐ Changes affect the cooling capacity to cool down and maintain the temperature of the liquid
	☐ Changes affect the functionality of the medium (refrigerant, water, etc.) to chill the system continuously
	☐ Changes may affect the power input specifications
	The data would be a place to the control of the property to the form of the control of the contr
	☐ Product currently has outdated testing or missing testing to the latest requirements. Requested to add in scope of the current project.
	*NSF456 Vaccine Impact Determination (Ref/Frz only):



TITLE: Regulatory Compliance Impact Assessment **RFV**: C

KEV	0	,								
	NICEAC	D DCC Impact I	Dotorm	sination (BCC anly).						
	NSF49 BSC Impact Determination (BSC only):									
	☐ Changes affect critical components in compliance files									
		Changes to the materials of construction or coatings (paint)								
		Changes impa	ct air flo	ow (blowers, power su	upp, filters, pa	per catch areas, fi	lter screen)			
		Changes to the	e softwa	are						
		Changes impa	cting st	ability (change weight	distribution of	or change to stand	s)			
			_			_		eners - Philip screws no	ot allowed)	
				abinet pressure decay	-			chero i imposiciro in	ze anomea,	
				s or markings (add, re						
				= :						
	ш	Product currei	ntly has	outdated testing or n	nissing testing	to the latest requ	irements. Re	equested to add in sco	be of the curr	ent project.
			N. Am	nerica	LATAM		EMEA		APAC	
	_		☐ EN	IERGY STAR*	☐ Clean Ro	om Particulate	□ Clean R	oom Particulate	☐ Clean Ro	om Particulate 14644-14*
	ţ ţ	Agency	□NS	F49 BSC*	14644-14*		14644-14*	•	1	rean Act on Environmental
	e .	Test		F456 Vaccine*	_			ective (Chillers only)	testing and	
	ر ا	Reports							_	Пізреспоп
	ဝ							Provide more informati	ion here.>	
	Impacted or Created		Cou	untry: <i><specify coเ<="" i="" the=""></specify></i>	untry where tl	his requirement is p	present>			
	ba	Marks &			/					
	틸	Labels	□ENE	ERGY STAR* □	CE (Self-Decla	red) 🗆 C	other (if appl	licable): < <i>If "Other" is s</i>	elected, provi	ide more information here.>
S		Documents	□ Ma	arketing claims	CE DoC (Self-I	Declared) 🗆 🗅	ther (if appl	icable): <if "other"="" is="" s<="" td=""><td>elected, provi</td><td>de more information here.></td></if>	elected, provi	de more information here.>
Ö					02 200 (00		тс. (арр.	iodoloji ilj otilol loo		ac more myormacion nerei-
ţ		Steps:	J. No +o	et contured Dational	a aravidad in	nlan				
; ;				st captured - Rational						
je				If "Other" is selected, _I	provide more	injormation nere.>	•			
Project Actions	-	pacted Docum								(6) 15:)
_		Agency Repo			•	ring Drawings/Doc		☐ Revise Regulator	y Documents	(Cloud Drive)
		Marketing cla			•	ns have not been	validation			
			-	duct, scope is defined						
		GEPC# <inse< td=""><td>rt GEPC</td><td>number if new projec</td><td>t is being cred</td><td>rted></td><td></td><td></td><td></td><td></td></inse<>	rt GEPC	number if new projec	t is being cred	rted>				
		l Other (if app	licable):	: <if "other"="" is="" selecte<="" td=""><td>d, provide mo</td><td>re information her</td><td>·e.></td><td></td><td></td><td></td></if>	d, provide mo	re information her	·e.>			
	Notif	ications to:								
	□ СВ	of changes (E	NERGY STAR, required if not testing) □ Energy Star Team Leads (ENERGY STAR)							
				tion Manufacturing Location South Korean RA Team for in-country Testing						
		· ·		Changes where registe				Other" is selected, prov	iide more infc	armation here >
	Au	thornes of th	ouuct c	shariges where registe	ircu		cubicj. vij	other is selected, prov	ide more mjo	Thation here.>
				DECLON CASES		IDELESS 001401	****			
								ESSMENT (All produ		
oxtimes Th	e chan	ge does not in	npact th	he design safety, EMC	, and/or wirel	ess compliance. Li	ke for like co	omponents (i.e., PCBA o	components)	should still be evaluated to
		, ,		not been impacted.						
Justifi	cation:	: For TFS PN#	49171H	103, MFR PN# GFRST1!	5W No safety	file update require	ed for UL file	no. E473332-D1017, S	A5215 sec.27	
	Mark	where applic	able							
	□ Do	es the change	e affect	specs, listings, warnin	igs, or text on	critical componen	ts in complia	ance files?		
Ħ		_		of the end product goin	_	•	-			
Б			0	of the product's enviro		, ,,		,		
Scope Assessme		-	-	es / use being impacte		io de changear (2)		.5) 564685) 216./		
ses		· ·		= :		nmhor.or.no+\2				
As		_	-	be changed (Keeping t	-					
e				omer facing informatio		•				
0			_	location or applicant		_				
Ň					•			for PCBA or enclosed s		
	☐ Product currently has outdated testing or missing testing to the latest accepted requirements. Requested to add in scope of the current project.						the current project.			
	□ Ot	her (if applica	able): <td>f "Other" is selected, p</td> <td>orovide more i</td> <td>information here.></td> <td>•</td> <td></td> <td></td> <td></td>	f "Other" is selected, p	orovide more i	information here.>	•			
				Safety Reports Impa	cted:			EMC Reports Impa	acted:	
				☐ NRTL Listing, Re		Report Number>		☐ EMC (EN rep	ort), Report #	<pre>! <insert number="" report=""></insert></pre>
		Agency Tes	t	☐ CB Safety, Repo	rt # <insert re<="" td=""><td>port Number></td><td></td><td>☐ FCC, Report</td><td># <insert rep<="" td=""><td>ort Number></td></insert></td></insert>	port Number>		☐ FCC, Report	# <insert rep<="" td=""><td>ort Number></td></insert>	ort Number>
		Reports		☐ Informative Safe		•	nher>	☐ ICES, Report		
10	eq			o.mative Jan	cc,, neport m	sere nepore ivan		· ·		: Report Number>
ű	eat			Other of "Oth	or" is colored	provide more info	rmation has			
Project Actions	Impacted or Created				i is selected,		rmuuon ner	e.>, Report # <insert r<="" td=""><td>sport Number</td><td>1</td></insert>	sport Number	1
t A	o Di	Marks & La	_	N. America		LATAM		EMEA		APAC
e C	3cte	Note: These ma may not be all	arkings		CSA	☐ IRAM-S		☐ CE DoC (Self-Decla	red)	☐ KC Mark
2	mp	inclusive. If ano	other		ΓUV	□ INMETRO		☐ CE DoC (EU NB)	ļ	□ EAC
	-	marking is used	l, this			□ ANATFI				



TITLE: Regulatory Compliance Impact Assessment

REV.	.: C						
	shall be place in the	□ FCC / ICES □ NSF	☐ S Mark	□ UKCA □ LNE			
	"Other" category.	□ NOM		□ GS □ WEEE			
		☐ Other: <select "other"="" if="" td="" the<=""><td>mark/label is not listed above.</td><td>Provide more information here.></td><td>•</td></select>	mark/label is not listed above.	Provide more information here.>	•		
		Country: <specify country<="" td="" the=""><td>ry where this requirement is pre</td><td>sent></td><td></td></specify>	ry where this requirement is pre	sent>			
		☐ FCC Declaration	No documents currently	☐ CE DoC (Self-Declared)	No documents currently		
	Documents		identified within this	☐ CE DoC (EU NB)	identified within this		
	*Indicates voluntary requirements		region.	☐ UKCA Declaration	region.		
		☐ Other: <select "other"="" if="" td="" the<=""><td>document is not listed above. Pi</td><td>rovide more information here.></td><td>·</td></select>	document is not listed above. Pi	rovide more information here.>	·		
			ry where this requirement is pre				
	Other (if applicable): Impacted Documents: No Update Required	test captured - Rationale provided If "Other" is selected, provide model I (justification within plan required ency required (FCC, etc.)	ore information here.>	inly Drawings/Documents (i.e., labels)			
		ocuments (i.e., declarations)		requirements due to changes.			
	= :	requirements due to changes.		requirements due to changes.			
	·	selected, provide more informatio					
	Notifications to:						
	☐ Regional Leads if regis	tered (i.e., Saudi SASO, KC Mark, A	Australian RCM)	olementation Manufacturing Locat	ion		
	☐ Authorities of Product	Changes where registered	Dother: </td <td>f "Other" is selected, provide more</td> <td>information here.></td>	f "Other" is selected, provide more	information here.>		
		END PRODUCT EN	IVIRONMENTAL ASSESSME	NT (All products)			
☐ The	e change does not impact t			ated with documentation updates)		
			· · · · · · · · · · · · · · · · · · ·	Prop 65) for proposed part GFR15V			
	Documents to reference f	for what is needed to meet enviror	nmental compliance:		·		
	CS Drawing# 260111S01	TC Dro	awing # 015955	MAR Drawing# GT	260111		
	Mark where applicable						
	☐ Change adds new or re	emoves any components from the	product (BOM update)				
	☐ The supplier of a part i	number is changing					
	\square The manufacturing or	internal part number is changing					
		currently has an outdated BOM i	n Greensoft or BOM is not uplo	aded into GreenSoft. Requested to	add in scope of the current		
ید	project.						
e l		elected, provide more information					
Sm	Internal Forms or	☐ GreenSoft Item Submission	☐ GreenSoft BOM Upload Fo		Collected Documents Form		
Ses	Agency Test Reports	☐ Other: < If "Other" is selected	· · · · · · · · · · · · · · · · · · ·	i e e e e e e e e e e e e e e e e e e e			
Scope Assessment	Marks & Labels	N. America	LATAM	EMEA	APAC		
be	Note: These markings may not	☐ Prop65	☐ WEEE	☐ WEEE ☐ F-Gas	☐ WEEE		
Scc	be all inclusive. If another	☐ FIFRA Pesticide (UV Lamp)		☐ PFAS	☐ China RoHS (C-RoHS)		
	marking is used, this shall be placed in the "Other" category.	□ Other: <select "other"="" above.="" here.="" if="" information="" is="" label="" listed="" mark="" more="" not="" provide="" the=""></select>					
			y where this requirement is pre		I		
		□ Prop65 Declaration □ Prop65 Dec	☐ Montreal Protocol	⊠ REACH Declaration	☐ C-RoHS "Tic-Tac Table"		
	Documents	☐ FIFRA Pesticide Product	Declaration	⊠ RoHS Declaration	Declaration		
	Note: If another document is needs to be created or update,	Reporting (UV Lamp)		☐ F-Gas Declaration			
	this shall be placed in the			☐ CE Declaration (Self-Declared)			
	"Other" category.	☐ Other: <select "other"="" above.="" coneg,="" document="" ex.="" here,="" if="" information="" is="" listed="" more="" not="" pfas.="" provide="" the=""></select>					

Country: <Specify the Country where this requirement is present>



TITLE: Regulatory Compliance Impact Assessment **RFV**: C

KEV	C
Project Actions	Next Steps: Testing Required: No test captured - Rationale provided in plan Other (if applicable): <if "other"="" here.="" information="" is="" more="" provide="" selected,=""> Impacted Documents: No Update Required Vupload GreenSoft Form(s) Revise Engineering Drawings/Documents (labels) Revise Regulatory Documents (i.e., declarations) Change impacts product, scope is defined as requiring a new project. GEPC# <insert being="" created="" gepc="" if="" is="" new="" number="" project=""> Other: <if "other"="" here.="" information="" is="" more="" provide="" selected,=""> Notifications to: GEPA Lead if registered (FIFRA) GreenSoft User to load GreenSoft BOM changes (i.e., component or supplier change − site: GS Submission) Other: <if "other"="" here.="" information="" is="" more="" provide="" selected,=""></if></if></insert></if>
	MEDICAL ASSESSMENT (Not applicable for General Purpose Products)
PΔRT	A SAFETY, COMPATIBILITY, EFFECTIVENESS
<i>(Mark</i> □ Wi □ Wi	if yes and complete Scope Assessment below) Il the change affect the safety, compatibility, or effectiveness of the device? Il the technology, engineering design, or performance of the device or packaging change? the change introducing a new material, or alternate component, or is it a supplier change?
Scope	□ Does the change include or impact the product's Intended use? □ Does the change introduce new risks of harm to humans, property, or the environment? □ Will the change affect the standards this product relies upon? □ Is there another registration classification that this product will align to? < Provide more information here.>
PART	B LABEL IMPACTS
(Mark	if yes and complete Scope Assessment below)
	Il the change affect product, packaging, electronic literature, or labelling?
Scope Assessment	Changes to Documents
Scope /	☐ Other: <if "other"="" here.="" information="" is="" more="" provide="" selected,=""> Changes to Product/Product Label ☐ Intended Use ☐ Translation(s) ☐ Change in specs/ratings ☐ Change in the warnings/precautions ☐ Other: <if "other"="" here.="" information="" is="" more="" provide="" selected,=""></if></if>
PART	C TECHNOLOGY, ENGINEERING, AND PERFORMANCE CHANGE
(Mark	if yes and complete Scope Assessment)
⊠ Wi	Il the technology, engineering design, performance of the device, or packaging change?
Scope Assessment	 □ Change in control mechanism, operating principle or energy type? □ Does the change impact the Product Requirements? □ Does the change impact a component that is subjected to sterilization, cleaning, or disinfection? □ Does the change to the part require that sterilization validation, cleaning validation, or disinfection validation should be repeated? □ Does the change affect the performance or accuracy of the device? □ Does the change involve a component, software/firmware item or other part responsible for the product achieving its intended use? □ Change in packaging design? □ Change uses the same technology and classification as described in a previously cleared 510(k) or 510(k) exempt version? □ Does the change impact safety critical (i.e., 61010, EMC), critical to quality, critical to performance components? (See ENG016, CTT Business Unit Engineering Change Control Process procedure for definitions.) □ Does the change affect the intended use of the device? □ Risk-based assessment of the changed device identify any new risks or significantly modified existing risks? □ Is clinical data necessary to evaluate the safety or effectiveness for purposes of design validation? D MATERIAL / SUPPLIER CHANGE
	if yes and complete Scope Assessment below) the change introducing a new material, alternate component, or is it a supplier change?



TITLE: Regulatory Compliance Impact Assessment

REV.: C

Scope Assessment	□ Is this a change in material type, material formulation, chemical composition, or the material's processing? □ Will the changed material directly or indirectly contact body tissues or fluids (Including operators and service)? □ Does a risk assessment identify any new or increased biocompatibility concerns? □ Has the manufacturer used the same material in a similar legally marketed device? □ Could the change affect the device's performance specifications? □ Does the supplier change impact split inspection locations and files? (Common for PCBA or enclosed subassemblies) □ Does the supplier change affect critical components in compliance files?						
Part	E SOF1	WARE/FIRMW	/ARE CHANGES				
•			e Assessment below) ct software or firmware?				
Scope Assessment	□ Does the SW Change impact the SW documentation? (as applicable SW QAPs/SOPs for AVL / MAR sites) □ Does the SW Change include a security patch related to a known vulgerability?						
			N. America	LATAM	EMEA	APAC	
Project Actions	Impacted or Created	Approvals & Registrations Note: These markings may not be all inclusive. If another marking is used, this shall be place in the "Other" category.	□ USA: FDA 510(K) Exempt □ USA: FDA 510(K) □ Canada: MDSAP □ Mexico: COFEPRIS □ Other: <select "other"="" <specify="" appropriate="" country:="" country<="" if="" th="" the=""><th></th><th></th><th>☐ China: NMPA ☐ Malaysia: MDA ☐ South Korea: MFDS ☐ Taiwan: TFDA ☐ India: CDSCO ☐ Singapore: HSA ☐ Japan: PMDA ☐ Australia: TGA ☐ Hong Kong: MCO ☐ Indonesia: MoH ☐ New Zealand: MEDSAFE</th></select>			☐ China: NMPA ☐ Malaysia: MDA ☐ South Korea: MFDS ☐ Taiwan: TFDA ☐ India: CDSCO ☐ Singapore: HSA ☐ Japan: PMDA ☐ Australia: TGA ☐ Hong Kong: MCO ☐ Indonesia: MoH ☐ New Zealand: MEDSAFE	
Project		Agency Test Reports	☐ IEC 60601 Report(s), Report # <insert number="" report=""> ☐ ILAC/IAAC Report, Report # <insert number="" report=""> ☐ CB Scheme Report, Report # <insert number="" report=""> ☐ CB Scheme Report, Report # <insert number="" report=""> ☐ Other: <select "other"="" above.="" here="" if="" information="" is="" listed="" more="" not="" provide="" report="" the="">, Report # <insert number="" report=""></insert></select></insert></insert></insert></insert>				
		Marks & Labels	☐ UDI ☐ CE (EU N☐ Other: < If "Other" is selected, I	·	ing/Shipping Labels	☐ Product Label	
	Tes O' Reg O' Ve Sul Otl	Steps: sting Required: Ir ther (if applicable gistration Impact ther (if applicable rify Intended Use bmit to EU NB her: < If "Other" is ications to:	n-house Testing e): c): c): c): c): c): d): d): f) "Other" is selected, provide m e consistency	ore information here.> ore information here.> leges documented in TF / DH I Update TF / DHF In here.>	F □ Ver	rify changes are documented in DMR rify 510k for change impact	
		gional RA Lead(s) tify Authorities o	☐ FDA Correspondent(s) of Product Changes where registered	•	☑ Notify RA at Implement is selected, provide more	entation Manufacturing Location information here.>	



TITLE: Regulatory Compliance Impact Assessment

REV.: C

Note: If more than one product type is identified, please ensure all responsible RA individuals have signed this document. Copy only the signature blocks as needed.

PROJECT PLAN ASSESSMENT (Completed during project phases)

- This is a drop-in replacement the proposed part (GFR15W) has similar or better specs than the current part (GFRST15W).
- For TFS PN# 49171H03, MFR PN# GFRST15W No safety file update required for UL file no. E473332-D1017, SA5215 sec.27. No EMI/EMC report update needed as well.
- FAI and Functional testing to be performed as per V-000150.
- Manual update is required, EPD for Manual update to capture GFCI details with new picture will be created after testing is completed.
- TSG models will be taken care by NPD team (EPD-004342).

 Update the Green soft template for submitting the documents for prop 	osed part.			
Regulatory Compliance EPD/ECR Assessment made by: Akanksha Fadtare	p			
Akanksha Fadtare	2024.6.06			
Signature	Date (YYYY.MM.DD)			
Engineering EPD/ECR Assessment made by: Madhu Nalla				
Madhu Nalla	2024.6.06			
Signature	Date (YYYY.MM.DD)			
Regulatory Compliance EPD/ECR Assessment approved by: Moriam Raji				
<insert in="" location="" signature="" this=""></insert>	<click a="" date.="" enter="" or="" tap="" to=""></click>			
Signature	Date (YYYY.MM.DD)			
PROJECT VERIFICATION ASSESSMENT (Completed before implementation of the design change) (Medical Only) Did any Design verification and/or validation activities produce any unexpected issues of safety or effectiveness? No - Design verification and/or validation activities did not produce any unexpected issues with safety or effectiveness. All affected reports were verified for change accuracy (CCL, models covered, content, etc.) and all documentation is stored in the Technical File (TF) of the product. Not a Medical Device Justification: As per approved test plan, all tests completed, and new part passed. All test results reviewed and approved by Tech pulse, Refer DVR document for test results. FAI: both GFCI and manual updates passed FAI Environmental declaration (REACH, RoHS and Prop65) provided. GS templates to be filled to upload the details in Greensoft tool. Regulatory Compliance EPD/ECR Assessment made by: Akanksha Fadtare				
Akanksha Fadtare	2024.6.13			
Signature	Date (YYYY.MM.DD)			
Engineering EPD/ECR Assessment made by: Madhu Nalla				
Madhu Nalla	2024.6.13			
Signature	Date (YYYY.MM.DD)			
Regulatory Compliance EPD/ECR Assessment approved by: Moriam Raji				
Moriam Zoji	2024.11.13			
Signature	Date (YYYY.MM.DD)			



TITLE: Regulatory Compliance Impact Assessment

REV.: C

APPENDIX 1 - DEFINITIONS

Control Mechanism	The manner by which the actions of a device are directed. An example of a change in control mechanism would be the replacement of an electromechanical control with a microprocessor control.
Compatibility	Capable of harmonious coexistence; said of two or more medications that are suitable for simultaneous administration without nullification or aggravation of their effects.
Critical to Quality	Components or sub-assemblies that include critical quality parameters that may impact the Quality of the product.
Critical to Safety	Components or sub-assemblies that include Critical to safety parameters. Examples include components listed in Safety Reports (i.e., 61010-1, 60601-1), Compliance Reports (EMC, FCC, IC, etc.). Components responsible for a medical device maintaining essential performance are also considered critical to Safety (see QAP402).
Design history file (DHF)	DHF means a compilation of records which describes the <i>design</i> history of a finished device. It is required for medical Class II and Class III FDA devices and medical devices manufactured under ISO 13485.
Device Master Record (DMR)	A device master record (DMR) contains all of the information and specifications needed to <i>produce</i> a medical device from start to finish, including instructions for all manufacturing processes, drawings, documented specifications and labeling and packaging requirements. This is required by the FDA for medical devices.
Effectiveness	The extent to which an action or object achieves its intended purpose.
Global Existing Product Change (GEPC)	A singular closed loop approach for change management with standardized terminology for post-design transfer changes to products and processes.
Harm	Physical injury or damage to the health of people
Hazard	Potential source of harm
Intended Use	The term "intended use" means the general purpose of the device or its function, and encompasses the indications for use
In Vitro Diagnostic Device (IVD)	Those reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. Such products are intended for use in the collection, preparation, and examination of specimens taken from the human body
Labeling	The term "labeling" means all labels and other written, printed, or graphic matter (1) upon any article or its containers or wrappers, or (2) accompanying such article. This can include, among other things, any user or maintenance manuals and, in some instances, promotional literature.
Material Formulation	The base formulation of a polymer, alloy, etc., plus any additives, colors, etc., used to establish a property or the stability of the material. This does not include processing aids, mold release agents, residual contaminants, or other manufacturing aids that are not intended to be a part of the material, but that could be present as impurities on the final device. An example of a change in material formulation would be a change from a series 300 stainless steel to a series 400 stainless steel. Another example of a change in material formulation would be the addition or subtraction of a chemical or compound to or from a polymer.
Material Type	The generic name of the material from which the device is manufactured. An example of a material type change would be the change from natural latex rubber to synthetic rubber.
Operating Principle	The mode of operation or mechanism of action through which a device fulfills (or achieves) its intended use. An example of a change in operating principle would be using a new algorithm to compress images in a picture archiving and communications system. For an IVD, an example would be a change from immunofluorescence to ELISA.
Packaging	Any wrapping, containers, etc., used to protect, to preserve the sterility of, or to group medical devices.
Performance Specifications	The performance characteristics of a device as listed in device labeling or in finished product release specifications. Some examples of performance specifications are measurement accuracy, output accuracy, energy output level, and stability criteria.
Risk	The combination of the probability of occurrence of harm and the severity of that harm. For the purposes of this document, may relate to either safety or effectiveness (e.g., risk of decreasing device effectiveness).
Safety	The state of being secure or safe from injury, harm, or loss; a judgment of the acceptability of risk—a measure of the probability of an adverse outcome and its severity associated with using a technology in a given situation
Software	The set of electronic instructions used to control the actions or output of a medical device, to provide input to or output from a medical device, or to provide the actions of a medical device. This definition includes software that is embedded within or permanently a component of a medical device, software that is an accessory to another medical device, or software that is intended to be used for one or more medical purposes that performs these purposes without being part of a hardware medical device.
Technical File (TF)	A technical file is a set of documents that describes a product and can prove that the product was designed in accordance with the requirements of a quality management system. This is mandatory for MDR products.
State of the Art	Developed stage of technical capability at a given time as regards products, processes, and services, based on the relevant consolidated findings of science, technology, and experience. Note: state of the art embodies what is currently and generally accepted as good practice in technology and medicine Does not necessarily imply the most technologically advanced solution
Unique Device Identifier (UDI)	Unique Device Identifier that is used on a medical device. Specific bar code on labels which are linked to a regulatory authority database (i.e., FDA).
User Interface	A device user interface includes all points of interaction between the product and the user, including elements such as displays, controls, packaging, product labels, and directions for use
Warnings	Warnings describe serious adverse reactions and potential safety hazards that can occur in the proper use or misuse of a device, along with consequent limitations in use and mitigating steps to take if they occur.



TITLE: Regulatory Compliance Impact Assessment

REV.: C

APPENDIX 2 - COMMON SOFTWARE CHANGE TYPES

Infrastructure	Changes are modifications made to the software support system. Examples include but are not limited to: switching compilers, changing programming
	languages (C to C++, C++ to Java), or changing software drivers or libraries.
Architecture	Changes are modifications to the overall structure of the software. Examples include but are not limited to: porting to a new OS, software changes to support a
	new hardware platform, and new middleware.
Core algorithm	Changes are modifications made to an algorithm that directly impact or contribute to the device's intended use. Examples include: alarm algorithms on a
	monitor, a motor control algorithm for an infusion pump, and a detection module and measurement engine algorithm for an IVD.
Clarification of	Changes made to clarify software requirements after a product has received premarket clearance. This clarification may be revised phrasing of an existing
Requirements – No	requirement or creation of a new requirement altogether, without changing or adding functionality.
Functionality Change	
Cosmetic Changes –	Changes made to the appearance of the device that do not impact the clinical use of the device. For example, changing the company logo that is displayed on
No Change to	the background of every screen could involve modifying multiple software modules; while the number of modules impacted may be large, it is unlikely that the
Functionality	intended change could significantly impact the device's safety and effectiveness or intended use
Re-engineering	Common software maintenance techniques. "Reengineering" is defined as the examination and alteration of software to reconstitute it in a new form, and
	includes the subsequent implementation of the new form. It is often undertaken to replace aging legacy software.
Refactoring	"Refactoring" is a disciplined technique for restructuring a software program's internal structure without changing its clinical performance specification.
	Refactoring seeks to improve a program structure and its maintainability. In general, reengineering often results in broader and more complex changes, while
	refactoring is often narrower in scope and less complex.